New Cutting-Edge GBI Research Reports Most Recently Published at MarketPublishers.com
02 Feb 2012 • by Natalie Aster
LONDON - Market Publishers Ltd informs that new cutting-edge market reports prepared by GBI Research have been added to its catalogue.
Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs. Rise in expenditures towards healthcare in the US has led to an increased life expectancy among the Americans. Out-of-pocket spending is minimal in the US, due to a strong reimbursement system provided by the public and private sector, that covers most age groups and communities. A majority of the US population is under insurance coverage, with private health insurance having a larger share than government health insurance. The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in the US with key data, information and analysis of pricing and reimbursement decisions across the country …
Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017. The world immunomodulators market is forecast to reach USD 259.3 billion in 2017 at a CAGR of 8.6%. With many of the major pharmaceutical companies like Roche, Amgen, and Johnson & Johnson expanding into this sector, R&D activity for immunomodulators will remain active for at least next four to five years. The report covers the global immunomodulators market, providing in-depth analysis and market forecasts of the major drug classes – immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). Key drivers and restraints, a competitive analysis of the top companies in the market can also be found in the study …
More new market reports by the publisher can be found at GBI Research page.